Prevalence of national treatment algorithm defined smear positive pulmonary tuberculosis in HIV positive patients in Brazzaville, Republic of Congo

BMC Research Notes

Francine Ntoumi⁵  Veronique Penlap³  Matthias Frank⁴  Sunny Oyakhirome¹  Gaston Bango Essassa⁶  Igor Kevin Madzou-Laboum⁶  Mitawa Missontsa²  Jeannhey C Vouvoungui²  Anissa Sidibé²  Pembe Issamou Mayengue²  Laure Stella Ghoma Linguissi² 

[1] Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of Congo;Faculté des Sciences de la Santé, Université Marien Ngouabi, Brazzaville PB 2672, Republic of Congo;University Yaoundé1, Yaoundé, Cameroon;German Center for Infection Research (DZIF), Braunschweig, Germany;Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany;Centre Antituberculeux de Brazzaville, Programme de Lutte contre la Tuberculose, Brazzaville, Republic of Congo

关键词: Republic of Congo;    HIV infection;    Pulmonary TB;    Microscopy;    Tuberculosis;   

Others  :  1130062
DOI  :  10.1186/1756-0500-7-578

 received in 2013-08-08, accepted in 2014-08-18,  发布年份 2014

【 摘 要 】

Background

In the Republic in Congo, the national algorithm for the diagnosis of pulmonary tuberculosis (TB) relies on Ziehl-Neelsen (ZN) sputum smear microscopy, chest X-ray radiography (CXR) and clinical symptoms. Microscopy positive pulmonary TB (MPT+) is defined as symptoms of TB and a positive ZN smear. Microscopy negative pulmonary TB (MPT-) is defined as symptoms of TB, a negative ZN smear but CXR changes consistent with TB. The present cross-sectional study was designed to determine the prevalence of positive and negative MPT individuals among HIV positive and HIV negative individuals presenting to an ambulatory TB treatment center (CTA) in Brazzaville.

Methods

All study participants underwent a physical examination, chest radiography and three ZN sputum smear examinations and HIV testing. Viral load and CD4 counts were determined for HIV positive individuals.

Results

775 individuals presented with symptoms of TB. 425 individuals accepted the voluntary HIV test. 133 (31.3%) were HIV positive (HIV+) and 292 (68.7%) were HIV negative (HIV-). Of the 292 HIV- individuals 167 (57%) were classified as positive MPT and 125 (43%) as negative MPT. Of the 133 HIV positive individuals 39 (29%) were classified as MPT + and 94 (71%) as MPT-.

Conclusion

Our study shows that the prevalence of positive MPT individuals is lower among HIV positive individuals compared to HIV negative individuals in agreement to reports from other countries. The data suggest that a substantial number of HIV positive pulmonary TB cases are not detected by the national algorithm and highlight the need for new diagnostic tests in this population.

【 授权许可】

   
2014 Linguissi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Wood R, Lawn SD, Caldwell J, Kaplan R, Middelkoop K, Bekker L-G, Bekker L-G: Burden of New and recurrent tuberculosis in a major south African city stratified by Age and HIV-status. PLoS One 2011, 6(10):e25098. doi:10.1371/journal.pone.0025098
• [2]World Health Organization: Global tuberculosis control report. WHO Report 2011. http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf webcite. Accessed on 4 July 2013
• [3]UNAIDS: Report on the global AIDS epidemic. 2012. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf webcite, available the 09/07/2013
• [4]Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, Kimerling ME, Chheng P, Thai S, Sar B, Phanuphak P, Teeratakulpisarn N, Phanuphak N, Nguyen HD, Hoang TQ, Le HT, Varma JK: An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010, 362(8):707-716.
• [5]Granich R, Akolo C, Gunneberg C, Getahun H, Williams P, Williams B: Prevention of tuberculosis in people living with HIV. Clin Infect Dis 2010, 50(Supplement 3):S215-S222. doi: 10.1086/651494
• [6]WHO, Stop TB Partnership: The Global Plan to Stop TB 2011–2015. Geneva: World Health Organization; 2011.
• [7]Gray F, Lescure FX, Adle-Biassette H, Polivka M, Gallien S, Pialoux G, Moulignier A: Encephalitis with infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment. Brain Pathol 2013. doi:10.1111/bpa.12038
• [8]Godfrey-Faussett P, Ayles H: Can we control tuberculosis in high HIV prevalence settings? Tuberculosis (Edinb) 2003, 83:68-76. PMID: 12758192
• [9]Tolu O, Burke R, Tsekela R, Bangani N, Seldon R, Gideon HP, Wood K, Wilkinson KA, Ottenhoff THM, Wilkinson RJ: High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax 2011, 66(8):669-673.
• [10]Corbett EL, Marston B, Churchyard GJ, De Cock KM: Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006, 367:926-937.
• [11]World Health Organization: Tuberculosis country profile: Congo. 2013. https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=CG&LAN=EN&outtype=html webcite. Accessed on 01 July 2013
• [12]Gray JM, Cohn DL: Tuberculosis and HIV coinfection. Semin Respir Crit Care Med 2013, 34(1):32-43. doi:10.1055/s-0032-1333469. Epub 2013 Mar 4
• [13]Martínez-Romero A, Ortega-Sánchez JL, González-Yañez MG, Hernández-Salgado JR, Ruíz-Baca E, Alba-Romero JJ, Cervantes-Flores M: Comparison of acid-fast bacilli smear and chromatographic immunoassay in patients with active tuberculosis. Afr J Microbiol Res 2012, 6(8):1690-1693.
• [14]Swai HF, Mugusi FM, Mbwambo JK: Sputum smear negative pulmonary tuberculosis: sensitivity and specificity of diagnostic algorithm. BMC Res Notes 2011, 4:475. BioMed Central Full Text
• [15]Brodie D, Schluger NW: The diagnosis of tuberculosis. Clin Chest Med 2005, 26:247-271.
• [16]Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, Bekker LG, Wood R: Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the xpert MTB/RIF assay: a prospective study. PLoS Med 2011, 8(7):e1001067. doi:10.1371/journal.pmed.1001067
• [17]Nahid P, Kim PS, Evans CA, Alland D, Barer M, Diefenbach J, Ellner J, Hafner R, Hamilton CD, Iademarco MF, Ireton G, Kimerling ME, Lienhardt C, MacKenzie WR, Murray M, Perkins MD, Posey JE, Roberts T, Sizemore C, Stevens WS, Via L, Williams SD, Yew WW, Swindells S: Clinical research and development of tuberculosis diagnostics: moving from silos to synergy. J Infect Dis 2012, 205:S159-S168.
• [18]Mugusi F, Villamor E, Urassa W, Saathoff E, Bosch RJ, Fawzi WW: HIV co-infection, CD4 cell counts and clinical correlates of bacillary density in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006, 10:663-669.
• [19]Harries AD, Zachariah R, Lawn SD: Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 2009, 13(1):6-16.
• [20]Padmanesan N, Wood J, MacIntyre CR, Mathai D: Risk factors for tuberculosis. Pulmonary medicine. 2013., 2013Article ID 828939. http://www.readcube.com/articles/10.1155/2013/828939?locale=en webcite
• [21]Dimairo M, MacPherson P, Bandason T, Zezai A, Munyati SS, Butterworth AE, Mungofa S, Rusikaniko S, Fielding K, Mason PR, Corbett EL: The risk and timing of tuberculosis diagnosed in smear-negative TB suspects: a 12 month cohort study in Harare, Zimbabwe. PLoS One 2010, 5(7):e11849. doi:10.1371/journal.pone.0011849
• [22]Brouwer M, Gudo PS, Simbe CM, Perdigão P, Van Leth F: Are routine tuberculosis programme data suitable to report on antiretroviral therapy use of HIV-infected tuberculosis patients? BMC Rese Notes 2013, 6:23. doi:10.1186/1756-0500-6-23 BioMed Central Full Text
• [23]Dowdy DW, Lourenço MC, Cavalcante SC, Saraceni V, King B, Golub JE, Bishai D, Durovni B, Chaisson RE, Dorman SE: Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One 2008, 3(12):e4057. doi:10.1371/journal.pone.0004057
• [24]Soumya S, Padmapriyadarsini C, Narendran G: HIV-associated tuberculosis: clinical update. Clin Infect Dis 2010, 50(10):1377-1386. doi:10.1086/652147
• [25]Cavanaugh JS, Shah NS, Cain KP, Winston CA: Survival among patients with HIV infection and smear-negative pulmonary tuberculosis – United States, 1993–2006. PLoS One 2012, 7(10):e47855. doi:10.1371/journal.pone.0047855
• [26]Benova L, Fielding K, Greig J, Nyang’wa B-T, Casas EC, da Fonseca , du Cros P: Association of BMI category change with TB treatment mortality in HIV-positive smear-negative and extrapulmonary TB patients in Myanmar and Zimbabwe. PLoS One 2012, 7(4):e35948. doi:10.1371/journal.pone.0035948
• [27]Padmapriyadarsini G, Swaminathan N, Swaminathan S: Diagnosis & treatment of tuberculosisin HIV co-infected patients. Indian J MedRes 2011, 134:850-865.
• [28]Foongladda S, Klayut W, Chinli R, Pholwat S, Houpt ER: Use of mycobacteriophage qPCR on MGIT broths for a rapid tuberculosis antibiogram. J Clin Microbiol 2014, 52:1523-1528. doi:10.1128/JCM.03637-13.
• [29]Lawn SD, Wood R: Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011, 204(suppl 4):S1159-S1167. doi:10.1093/infdis/jir411
• [30]Rossato Silva D, Müller AM, Tarso Roth Dalcin DP: Factors associated with delayed diagnosis of tuberculosis in hospitalized patients in a high TB and HIV burden setting: a cross-sectional study. BMC Infect Dis 2012, 12:57. doi:10.1186/1471-2334-12-57 BioMed Central Full Text
• [31]Adeiza MA, Abba AA, Okpapi JU: HIV-associated tuberculosis: a sub-Saharan African perspective. 2014, 1(1):1-14.
• [32]Alvarez-Uria G, Naik PK, Pakam R, Bachu L, Midde M: Natural history and factors associated with early and delayed mortality in HIV-infected patients treated of tuberculosis under directly observed treatment short-course strategy: a prospective cohort study in India. Interdiscip Perspect Infect Dis 2012., 2012Article ID 502012, 9 pages. http://dx.doi.org/10.1155/2012/502012 webcite
• [33]Desikan P: Sputum smear microscopy in tuberculosis: is it still relevant? Indian J Med Res 2013, 137:442-444.
• [34]Perkins MD: New diagnostic tools for tuberculosis. Int J Tuberc Lung Dis 2000, 12(2):S182-S188.
• [35]Huerga H, Varaine F, Okwaro E, Bastard M, Ardizzoni E, Sitienei J, Chakaya J, Bonnet M: Performance of the 2007 WHO algorithm to diagnose smear-negative pulmonary tuberculosis in a HIV prevalent setting. PLoS One 2012, 7(12):e51336. doi:10.1371/journal.pone.0051336
• [36]Hoffmann CJ, Variava E, Rakgokong M, Masonoke K, van der Watt M, Chaisson RE, Martinson NA: High prevalence of pulmonary tuberculosis but Low sensitivity of symptom screening among HIV-infected pregnant women in South Africa. PLoS One 2013, 8(4):e62211. doi:10.1371/journal.pone.0062211
• [37]Davis JL, Worodria W, Kisembo H, Metcalfe JZ, Cattamanchi A, Kawooya M, Kyeyune R, den Boon S, Powell K, Okello R, Yoo S, Huang L: Clinical and radiographic factors Do Not accurately diagnose smear-negative tuberculosis in HIV-infected inpatients in Uganda: a cross-sectional study. PLoS One 2010, 5(3):e9859.
• [38]Mayer K: Immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009, 48(1):101-107. doi:10.1086/595006
• [39]Swindells S, Komarow L, Tripathy S, Cain KP, MacGregor RR, Achkar JM, Gupta A, Veloso VG, Asmelash A, Omoz-Oarhe AE, Gengiah S, Lalloo U, Allen R, Shiboski C, Andersen J, Qasba SS, Katzenstein DK, AIDS Clinical Trials Group 5253 Study Team: Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS clinical trials group protocol A5253. Int J Tuberc Lung Dis 2013, 17(4):532-539. doi:10.5588/ijtld.12.0737
• [40]Narendran G, Selvakumar N, Risbud AR, Sheta D, Rajasekaran S, Thomas A, Wares F, Swaminathan S: Evaluation of a diagnostic algorithm for sputum smear-negative pulmonary tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr 2013, 63(3):331-338. doi:10.1097/QAI.0b013e31829341af
• [41]World Health Organization: Tuberculosis diagnostics xpertmtb/Rif test. WHO Endorsement and Recommendations 2010. http://www.who.int/tb/features_archive/factsheet_xpert_may2011update.pdf webcite. Accessed on July 3, 2013
• [42]O'Grady J, Bates M, Chilukutu L, Mzyece J, Cheelo B, Chilufya M, Mukonda L, Mumba M, Tembo J, Chomba M, Kapata N, Maeurer M, Rachow A, Clowes P, Hoelscher M, Mwaba P, Zumla A: Evaluation of the xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection Are highly endemic. Clin Infect Dis 2012, 55(9):1171-1178. doi:10.1093/cid/cis631
• [43]Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N: Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013., (1) Art. No.: CD009593. doi:10.1002/14651858.CD009593.pub2
• [44]Carriquiry G, Otero L, González-Lagos E, Zamudio C, Sánchez E, Nabeta P, Campos M, Echevarría J, Seas C, Gotuzzo E: A diagnostic accuracy study of Xpert®MTB/RIF in HIV-positive patients with high clinical suspicion of pulmonary tuberculosis in Lima, Peru. PLoS One 2012, 7(9):e44626. doi:10.1371/journal.pone.0044626
• [45]Lawn SD, Kerkhoff AD, Vogt M, Wood R: Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012, 12(3):201-209. doi:10.1016/S1473-3099(11)70251-1. Epub 2011 Oct 17
• [46]Lawn SD: Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis 2012, 12:103. doi:10.1186/1471-2334-12-103. Review BioMed Central Full Text